Abstract
Despite that clinical trials have been examining the safety profile of coronavirus disease 2019 (COVID-19) vaccines, there are concerns about long-term side effects as the number of vaccinations increases. Herein, we report a case of new-onset renal-limited anti-myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis after booster vaccination with the mRNA 1273 (Moderna) vaccine. A 72-year-old woman with no specific past history, and who had a normal renal function, developed ANCA-associated vasculitis following heterologous booster with mRNA1273 (Moderna) vaccine. After a kidney biopsy, she was diagnosed with ANCA-associated pauci-immune crescentic glomerulonephritis. Her renal function and constitutional symptoms have been improved with treatment with plasmapheresis, intravenous cyclophosphamide and steroid pulse therapy (intravenous 500 mg of methylprednisolone sodium succinate for 3 days) followed by a reduced steroid regimen.
Keywords: ANCA-Vasculitis; Heterologous; mRNA1273 COVID-19 Vaccine.
【저자키워드】 Heterologous, ANCA-vasculitis, mRNA1273 COVID-19 Vaccine., 【초록키워드】 COVID-19, Methylprednisolone, Treatment, coronavirus disease, Coronavirus disease 2019, Vaccine, vaccination, clinical trial, therapy, Vaccines, antibody, sodium, MPO, Symptom, renal function, Methylprednisolone sodium succinate, kidney, Glomerulonephritis, mRNA, mRNA1273, Vasculitis, Plasmapheresis, safety profile, Heterologous, booster, Moderna, booster vaccination, steroid, intravenous, Cyclophosphamide, regimen, followed by, Side effect, crescentic glomerulonephritis, past history, constitutional symptoms, Antineutrophil cytoplasmic antibody, Increases, sodium succinate, pulse, diagnosed, reduced, cytoplasmic, 【제목키워드】 COVID-19, report,